Abstract
There is a constellation of diseases whose pathology is a direct consequence of the immune response. Since there has been a failure to identify either an infectious aetiology or a pathognomonic immune abnormality, these diseases are characterized as being autoimmune. Rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis and multiple sclerosis are all well-known examples. An important therapeutic approach to these diseases is the selective inhibition of immune activity.
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Meuer, SC, Acuto, O et al. (1984). The human T-cell receptor. Annu Rev Immunol, 2, 23–50
Brenner, MB, McLean, J, Dialynas, DP et al. (1986). Identification of a putative second T-cell receptor. Nature, 322, 145–149
Koning, F, Kruisbeek, AM, Maloy, WL et al. (1988). T Cell receptor gamma/delta chain diversity. J Exp Med, 167, 676–681
Babbitt, BP, Allen, PM, Matsueda, G et al. (1985). Binding of immunogenic peptides to Ia histocompatibility molecules. Nature, 317, 359–361
Buus, S, Sette, A, Colon, SM et al. (1987). The relationship between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science, 235, 1353–1358
Gregerson, PK, Silver, J and Winchester, RJ (1987). The shared epitope hypothesis: An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum, 30, 1205–1213
Christadoss, P, Lindstrom, JM, Melvoid, R and Talal, N (1985). Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis. Immunogenetics, 21, 33–38
Rivas, A, Takada, S, Koide, J et al. (1988). CD4 molecules are associated with the antigen receptor complex on activated but not resting T cells. J Immunol, 140, 2912–2918
Campbell, IL, Oxbrow, L, Koulmanda, M and Harrison, LC (1988).IFN-γ induces islet cell MHC antigens and enhances autoimmune, streptozotocin-induced diabetes in the mouse. J Immunol, 140, 1111–1116
McDonald, AH and Swanborg, RH (1988). Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. J Immunol, 140, 1132–1118
Mosmann, TR and Coffman, RL (1987). Two types of mouse helper T-cell clones. Implications for immune regulation. Immunol Today, 8, 223–227
Janeway, CA, Jr, Carding, S, Jones, B et al. (1987). CD4+ T cells: specificity and function. Immunol Rev, 101, 39–80
Arthur, RP and Mason, D (1986). T cells that help B cell response to soluble antigen are distinguishable from those producing interleukin 2 on mitogenic or allogeneic stimulation. J Exp Med, 163, 774–786
Reinherz, EL, Morimoto, C et al. (1982). Heterogeneity of human T4+ inducer T cells defined by a monoclonal antibody that delineates two functional subpopulations. J Immunol, 128, 463–468
Greenbaum, LA, Horowitz, JB, Wood, A et al. (1988). Autocrine growth of CD4+ T cells. Differential effects of IL-1 on helper and inflammatory T cells. J Immunol, 140, 1555–1560
Trenn, G, Takayama, H, Hu-Li, J et al. (1988). B cell stimulatory factor 1 (IL-4) enhances the development of cytotoxic T cells from Lyt-2+ resting murine T lymphocytes. J Immunol, 140, 1101–1106
Duke, O, Panayi, GS, Janossy, G and Poulter, LW (1982). An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol, 49, 22–30
Klareskog, L, Forsum, U, Wigren, A and Wigzell, H (1982). Relationships between HLA-DR-expressing cells and T lymphocytes of different subsets in rheumatoid synovial tissue. Scand J Immunol, 15, 501–507
Young, CL, Adamson, III, TC, Vaughan, JH and Fox, RI (1984). Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. Arthritis Rheum, 27, 32–39
Rose, LM, Ginsberg, AH, Rothstein, TL et al. (1985). Selective loss of a subset of T helper cells in active multiple sclerosis. Proc Natl Acad Sci USA, 82, 7389–7393
Sato, K, Miyasaka, N, Yamaoka, K et al. (1987). Quantitative defect of CD4+2H4 + cells in systemic lupus erythematosus and Sjögren’s syndrome. Arthritis Rheum, 30, 1407–1411
Morimoto, C, Reinherz, EL, Borel, Y et al. (1981). Autoantibody to an immunoregulatory inducer population in patients with juvenile rheumatoid arthritis. J Clin Invest, 67, 753–761
Emery, P, Gentry, KC, MacKay, IR et al. (1987). Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis. Arthritis Rheum, 30, 849–856
Lasky, HP, Bauer, K and Pope, RM (1988). Increased helper inducer and decreased suppressor inducer phenotypes in the rheumatoid joint. Arthritis Rheum, 31, 52–59
Greiner, DL, Handler, ES, Nakano, K et al. (1986). Absence of the RT-6 T cell subset in diabetes-prone BB/W rats. J Immunol, 136, 148–151
Greiner, DL, Mordes, JP, Handler, ES et al. (1987). Depletion of RT6.1+ T lymphocytes induces diabetes in resistant biobreeding/Worcester (BB/W) rats. J Exp Med, 166, 461–475
Holmdahl, R, Jonsson, R, Larsson, P and Klareskog, L (1988). Early appearance of activated CD4+ T lymphocytes and class II antigen-expressing cells in joints of DBA/1 mice immunized with type II collagen. Lab Invest, 58, 53–60
Holmdahl, R, Rubin, K, Klareskog, L et al. (1985). Appearance of different lymphoid cells in synovial tissue and peripheral blood during the course of collagen II-induced arthritis in rats. Scand J Immunol, 21, 197–204
Klareskog, L, Holmdahl, R, Larsson, E and Wigzell, H (1983). Role of T lymphocytes in collagen II induced arthritis in rats. Clin Exp Immunol, 51, 117–125
Sriram, S, Solomon, D, Rouse, RV and Steinman, L (1982). Identification of T cell subsets and B lymphocytes in EAE lesions. J Immunol, 129, 1649–1651
Whittum, J, Goldschneider, I, Greiner, D and Zurier, R (1985). Developmental abnormalities of terminal deoxynucleotidyl transferase positive bone marrow cells and thymocytes in New Zealand mice: Effects of prostaglandin E1. J Immunol, 135, 272–280
Ridge, SC, Zabriske, JB, Oronsky, AL and Kerwar, SS (1985). Streptococcal cell wall arthritis: studies with nude (athymic) inbred Lewis rats. Cell Immunol, 96, 231–234
Allen, JB, Malone, DG, Wahl, SM et al. (1985). Role of the thymus in streptococcal cell wall-induced arthritis and hepatic granuloma formation: comparative studies of pathology and cell wall distribution in athymic and euthymic rats. J Clin Invest, 76, 1042–1056
Yocum, DE, Allen, JB, Wahl, SM et al. (1986). Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats. Arthritis Rheum, 29, 262–273
Holoshitz, J, Naparstek, Y, Ben Nun, A and Cohen, IR (1983). Lines of T lymphocytes induce or vaccinate against autoimmune arthritis. Science, 219, 56–58
van Eden, W, Holoshitz, J, Nevo, Z et al. (1985). Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. Proc Natl Acad Sci USA, 82, 5117–5120
Trentham, DE, Dynesius, RA and David, JR (1978). Passive transfer by cells of type II collagen-induced arthritis in rats. J Clin Invest, 62, 359–366
Holmdahl, R, Klareskog, L, Rubin, K et al. (1985). T lymphocytes in collagen type II arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol, 22, 295–306
Seki, N, Sudo, Y, Yoshioka, T et al. (1988). Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. J Immunol, 140, 1477–1484
Romball, CG and Weigle, WO (1987). Transfer of experimental autoimmune thyroiditis with T cell clones. J Immunol, 138, 1092–1098
Pettinelli, CE and McFarlin, DE (1981). Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vivo activation of lymph node cells by myelin basic protein: requirement for Lyt l+2- T lymphocytes. J Immunol, 127, 1420–1423
Ben-Nun, A, Wekerle, H and Cohen, IR (1981). The rapid isolation of clonable antigen specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol, 11, 195–199
Zamvil, S, Nelson, P, Trotter, J et al. (1985). T cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature, 317, 355–358
Pelletier, L, Pasquier, R, Rossert, J et al. (1988). Autoreactive T cells in mercury-induced autoimmunity. Ability to induce the autoimmune disease. J Immunol, 140, 750–754
Helfgott, SM, Kieval, RI, Breedveld, FC et al. (1988). Detection of arthritogenic factor in adjuvant arthritis. J Immunol, 140, 1838–1843
Watanabe, R, Wege, H and ter Meulen, V (1983). Adoptive transfer of EAE-like lesions from rats with coronavirus-induced demyelinating encephalomyelitis. Nature, 305, 150–153
Neu, N, Rose, NR, Beisel, KW et al. (1987). Cardiac myosin induced myocarditis in genetically predisposed mice. J Immunol, 139, 3630–3636
Schluesener, HJ, Sobel, RA, Linington, C and Weiner, HL (1987). A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol, 139, 4016–4021
Wofsy, D, Ledbetter, JA, Hendler, PL and Seaman, WE (1985). Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol, 134, 852–857
Wofsy, D (1986). Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. J Immunol, 136, 4554–4560
Ranges, GE, Sriram, S and Cooper, SM (1985). Prevention of type II collagen arthritis by in vivo treatment with anti-L3T4. J Exp Med, 162, 1105–1110
Brostoff, SW and Mason, DW (1984). Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J Immunol, 133, 1938–1942
Waldor, MW, Sririam, S, Hardy, R et al. (1985). Reversal of experimental allergic encephalomyelitis with a monoclonal antibody to a T cell subset marker. Science, 227, 415–417
Sriram, S and Roberts, CA (1986). Treatment of established chronic relapsing experimental allergic encephalitis with anti-L3T4 antibodies. J Immunol, 136, 4464–4469
Christadoss, P and Dauphinee, MJ (1986). Immunotherapy for myasthenia gravis: a murine model. J Immunol, 136, 2437–2440
Wang, Y, Hao, L, Gill, RG and Lafferty, KJ (1987). Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent. Diabetes, 36, 535–538
Wofsy, D and Seaman, WE (1985). Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med, 161, 378–391
Bank, I and Chess, L (1985). Perturbations of the T4 molecule transmits a negative signal to T cells. J Exp Med, 162, 1294–1303
Tite, JP, Sloan, A and Janeway, Jr, CA (1986). The role of L3T4 in T cell activation: L3T4 may be both an Ia-binding protein and a receptor that transduces a negative signal. J Mol Cell Immunol, 2, 179–190
Seaman, WE and Wofsy, D (1988). Selective manipulation of the immune response in vivo by monoclonal antibodies. Annu Rev Med, 39, 231–241
Waldor, MK, Mitchell, D, Kipps, TJ et al. (1987). Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody. J Immunol, 139, 3660–3664
Brostoff, SW and White, TM (1986). Treatment of clinical experimental allergic encephalitis in the rat with monoclonal antibody. J Neuroimmunol, 13, 233–240
Carteron, NL, Wofsy, D and Seaman, WE (1988). Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J Immunol, 140, 713–716
Rodriguez, M and Sririam, S (1988). Successful therapy of Theiler’s virus-induced demyelination (DA strain) with monoclonal anti-Lyt-2 antibody. J Immunol, 140, 2950–2955
Steinman, L, Rosenbaum, JT, Sriram, S and McDevitt, HO (1981). In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci USA, 78, 7111–7114
Sriram, S and Steinman, L (1983). Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes. J Exp Med, 158, 1362–1369
Perry, LL and Green MI (1982). Conversion of immunity to suppression by in vivo administration of I-A subregion-specific antibodies. J Exp Med, 156, 480–491
Steinman, L, Solomon, D, Lim, M et al. (1983). Prevention of experimental allergic encephalitis with in vivo administration of anti I-A antibody: decreased accumulation of radiolabelled lymph node cells in the central nervous system. J Neuroimmunol, 5, 91–97
Sriram, S, Topham, DJ and Carroll, L (1987). Haplotype-specific suppression of experimental allergic encephalomyelitis with anti-IA antibodies. J Immunol, 139,1485–1489
Adelman, NE, Watling, D and McDevitt, HO (1983). Treatment of NZB/W F1 disease with anti-I-A monoclonal antibodies. J Exp Med, 158, 1350–1355
Rosenbaum, JT, Adelman, NE and McDevitt, HO (1981). In vivo effects of antibodies to immune response gene products. I. Haplotype specific suppression of humoral immune responses with a monoclonal anti-I-A. J Exp Med, 154, 1694–1702
Vladutiu, AO and Steinman, L (1987). Inhibition of autoimmune thyroiditis in mice by anti-I-A antibodies. Ceil Immunol, 109, 169–180
Wooley, PH, Luthra, HS, Lafuse, WP et al. (1985). Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-Ia antisera. J Immunol, 134, 2366–2374
Waldor, MK, Sriram, S, McDevitt, HO and Steinman, L (1983). In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc Natl Acad Sci USA, 80, 2713–2717
Ben-Nun, A, Wekerle, H and Cohen, IR (1981). Vaccination against autoimmune encephalomyelitis with T lymphocyte line cells reactive against myelin basic protein. Nature, 292, 60–63
Ellerman, KE, Powers, JM and Brostoff, SW (1988). A suppressor T-lymphocyte cell line for autoimmune encephalomyelitis. Nature, 331, 265–267
Maron, R, Zerubavel, R, Friedman, A and Cohen, IR (1983). T lymphocyte line specific for thyroglobulin produces or vaccinates against autoimmune thyroiditis in mice. J Immunol, 131, 2316–2322
Brahn, E and Trentham, DE (1987). Attenuation of collagen arthritis and modulation of delayed-type hypersensitivity by type II collagen reactive T-cell lines. Cell Immunol, 109, 139–147
Kakimoto, K, Katsuki, M, Hirofuji, T et al. (1988). Isolation of T cell line capable of protecting mice against collagen-induced arthritis. J Immunol, 140, 78–83
Sano, S, Suda, T, Qian, J-H et al. (1987). Abrogation of the capacity of delayed-type hypersensitivity responses to alloantigens by intravenous injection of neuraminidase-treated allogeneic cells. J Immunol, 139, 3652–3659
Hahn, BH and Ebling, FM (1984). Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA. J Immunol, 132, 187–190
Fritz, RB and Desjardins, AE (1982). Idiotypes of Lewis rat antibodies to encephalitogenic peptides of guinea pig myelin basic protein: in vitro and in vivo studies. J Immunol, 128, 247–250
Lennon, VA and Lambert, EHJ (1981). Monoclonal autoantibodies to acetyl choline receptors: evidence for a dominant idiotype and requirement of complement for pathogenicity. Ann NY Acad Sci, 377, 77–96
Hahn, BH and Ebling, FM (1983). Suppression of NZB/NZW murine nephritis by administration of a syngeneic monoclonal antibody to DNA: Possible role of anti-idiotypic antibodies. J Clin Invest, 71, 1728–1736
Christadoss, P, Lennon, VA and David, C (1979). Genetic control of experimental autoimmune myasthenia gravis in mice: I. Lymphocyte proliferative response to acetylcholine receptor is under H-2-linked Ir gene control. J Immunol, 123, 2540–2543
De Baets, MC, Einarson, B, Lindstrom, JM and Weigle, WO (1982). Lymphocyte activation in experimental autoimmune myasthenia gravis. J Immunol, 128, 2228–2235
Krolick, KA and Urso, OE (1986). Influence of T cell specificity on the antibody response to the acetylcholine receptor. J Neuroimmunol, 13, 75–87
Neilson, EG and Phillips, SM (1982). Suppression of interstitial nephritis by auto-anti-idiotypic immunity. J Exp Med, 155, 179–189
Neilson, EG, McCafferty, E, Phillips, SM et al. (1984). Antiidiotypc immunity in interstitial nephritis. II. Rats developing anti-tubular basement membrane disease fail to make an antiidiotypic regulatory response: the modulatory role of an RT7.1+, OX8- suppressor T cell mechanism. J Exp Med, 159, 1009–1026
Stamenkovic, I, Stegagno, M, Wright, KA et al. (1988). Clonal dominance among T lymphocyte infiltrates in arthritis. Proc Natl Acad Sci USA, 85, 1179–1183
Butcher, EC (1986). The regulation of lymphocyte traffic. Curr Top Microbiol Immunol, 128, 85–122
Hamann, A, Jablonski-Westlich, D, Scholz, K-U et al. (1988). Regulation of lymphocyte homing. I. Alterations in homing receptor expression and organ-specific high endothelial venule binding of lymphocytes upon activation. J Immunol, 140, 737–743
Mountz, JD, Gause, WC, Finkelman, FD and Steinberg, AD (1988). Prevention of lymphadenopathy in MRL/lpr/lpr mice by blocking peripheral lymph node homing with Mel-14 in vivo. J Immunol, 140, 2943–2949
Kelley, VE, Gaulton, GN, Hattori, M et al. (1988). Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol, 140, 59–61
Kelley, VE, Gaulton, and Strom, TB (1987). Inhibitory effects of anti-interleukin 2 receptor and anti-L3T4 antibodies on delayed type hypersensitivity: the role of complement and epitope. J Immunol, 138, 2771–2775
Kumar, A, Moreau, J-L, Gibert, M and Thèze, J (1987). Internalization of interleukin 2 (IL-2) by high affinity IL-2 receptors is required for the growth of IL-2-dependent T cell lines. J Immunol, 139, 3680–3684
Murphy, JR, Bishai, W, Borowski, M et al (1986). Genetic construction expression and melanoma selective cytotoxicity of a diptheria toxin-related α-melanocyte-stimulating hormone fusion protein. Proc Natl Acad Sci USA, 83, 8258–8262
Vitetta, ES and Uhr, JW (1985). Immunotoxins. Ann Rev Immunol, 3, 197–212
Kelley, VE, Bacha, P, Pankewycz, O et al. (1988). Interleukin-2 toxin fusion protein abolishes cell mediated immunity in vivo. Proc Natl Acad Sci USA, 85, 3980–3984
Kelley, VE, Naor, D, Tarcic, N et al. (1986). Anti-interleukin 2 receptor antibody suppresses delayed-type hypersensitivity to foreign and syngeneic antigens. J Immunol, 137, 2122–2124
Nepom, GT, Hansen, JA and Nepom, BS (1987). The molecular basis for HLA class II associations with rheumatoid arthritis. J Clin Immunol, 7, 1–7
Warren, MK and Vogel, SN (1985). Opposing effects of glucocorticoids on interferon-γ-induced murine macrophage Fc receptor and Ia antigen expression. J Immunol, 134, 2462–2469
Collins, T, Korman, AJ, Wake, CT et al. (1984). Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA, 81, 4917–4921
Fontana, A, Fierz, W and Wekerle, H (1984). Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature, 307, 273–276
Fierz, W, Endler, B, Reske, K et al. (1985). Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol, 134, 3785–3793
Jacob, CO, van der Meide, PH and McDevitt, HO (1987). In vivo treatment of (NZB x NZW)F1 lupus-like nephritis with monoclonal antibody to 7-interferon. J Exp Med, 166, 798–803
Remy, J-J, Salamero, J, Michel-Bechet, M and Charreire, J (1987). Experimental autoimmune thyroiditis induced by recombinant interferon-γ. Immunol Today, 8, 73
Heremans, H, Dijkmans, R, Sobis, H et al. (1987). Regulation by interferons of the local inflammatory response to bacterial lipopolysaccharide. J Immunol, 138, 4175–4179
Billiau, A, Heremans, H, Vandekerckhove, F et al. (1988). Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ. J Immunol, 140, 1506–1510
Ottemess, IG and Chang, Y-H (1976). Comparative study of cyclophosphamide, 6-mercaptopurine, azathiaprine and methotrexate. Relative effects on the humoral and cellular immune response in the mouse. Clin Exp Immunol, 26, 346–354
Lombardino, JG and Otterness, IG (1981). Novel immunosuppressive agents. Potent immunological activity of some benzothiopyrano[4,3-c]pyrazol-3-ones. I Med Chem, 24, 830–834
Ottemess, IG (1981). Comparative activity of CP-17,193 and five established immunosuppressives towards the antigens SRBC and EL4. Clin Exp Immunol, 46, 332–339
Otterness, IG and Bliven, ML (1984). Pharmacologic modulation of immune function: some considerations for design of drug therapy. Adv Inflam Res, 7, 185–199
Kino, T, Hatanaka, H, Hashimoto, N et al. (1987). FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot, 40, 1249–1255
Hess, AD and Tutschka, PJ (1980). Effect of CsA on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR. J Immunol, 124, 2601–2608
Andrus, L and Lafferty, KJ (1982). Inhibition of T cell activity by cyclosporin A. Scand I Immunol, 15, 449–458
Krusemeier, M and Snow, EC (1988). Induction of lymphokine responsiveness of hapten-specific B lymphocytes promoted through an antigen-mediated T helper lymphocyte intereaction. J Immunol, 140, 367–375
Sideras, P, Funa, K, Zalcberg-Quintana, I et al. (1988). Analysis by in situ hybridization of cells expressing mRNA for interleukin 4 in the developing thymus and in peripheral lymphocytes from mice. Proc Natl Acad Sci USA, 85, 218–221
Reem, GH, Cook, LA and Vilcek, J (1983). Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by CsA. Science, 221, 63–65
Herold, KC, Lancki, DW, Moldwin, RL and Fitch, FW (1986). Immunosuppressive effects of cyclosporin A on cloned T cells. J Immunol, 136, 1315–1321
Palacios, R (1982). Mechanism of T cell activation: role and functional relationship of HLA-DR antigens and interleukins. Immunol Rev, 63, 73–110
Lillehoj, HS, Malek, TR and Shevach, EM (1984). Differential effects of cyclosporin A on the expression of T and B lymphocyte activation antigens. J Immunol, 133, 244–250
Prince, HE and John, JK (1986). Cyclosporin inhibits the expression of receptors for interleukin 2 and transferrin on mitogen-activated human T lymphocytes. Immunol Invest, 15, 463–472
Larsson, E-L (1980) Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J Immunol, 124, 2828–2833
Miyawaki, T, Yachie, A, Ohzeki, S et al. (1983). Cyclosporin A does not prevent expression of the Tac antigen, a probable TCGF receptor molecule on mitogen-stimulated T cells. I Immunol, 130, 2737–2742
Dos Reiss, GA and Shevach, EM (1982). Effect of cyclosporin A on T cell function in vitro: the mechanism of suppression of T cell proliferation depends on the nature of the T cell stimulus as well as the differentiation state of the responding T cell. J Immunol, 129, 2360–2367
Ryffel, B, Muller, S and Foxwell, BC (1987). Cyclosporin-A allows the expression of high-affinity interleukin-2 binding sites on anti-T-cell antibody activated human T lymphocytes. Trans Proc, 19, 1199–1201
Colombani, PM, Robb, A and Hess, AD (1985). Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes. Science, 228, 337–339
Russell, DH, Kibler, DH, Matrisian, L, Larson, DF, Poulos, B and Magiin, BE (1985). Prolactin receptors on human T and B lymphocytes: antagonism or prolactin binding of cyclosporine. J Immunol, 134, 3027–3031
Larson, DF (1986). Mechanism of action: antagonism of the prolactin receptor. Prog Allergy, 38, 222–238
Fidelus, RK, Laughter, AH, Twomey, JJ et al. (1984). The effect of cylosporine on ornithine decarboxylase induction with mitogens, antigens and lymphokines. Transplantation, 37, 383–387
Rosoff, PM and Terres, G (1986). Cyclosporin A inhibits CA2+ dependent stimulation of the Na+/H+ antiport in human T cells. J Cell Biol, 103, 457–463
Handschumacher, RE, Harding, MW, Rice, J et al. (1984). Ctyclophilin: a specific cytosolic binding protein for cyclosporin A. Science, 226, 544–547
Borel, JF and Gunn, HC (1986). Cyclosporine as a new approach to therapy of autoimmune diseases. Ann NY Acad Sci, 475, 307–309
Mountz, JD, Smith, HR, Wilder, RL et al. (1988). Cs-A therapy in MRL-lpr/lpr mice: amerlioration of immunopathology despite autoantibody production. J Immunol, 138, 157–163
Gunn, HC and Ryffel, B (1986). Successful treatment of autoimmunity in (NZB x NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: II. reduction of glomerulonephritis. Clin Exp Immunol, 64, 234–242
Jones, MG and Harris, G (1985). Prolongation of life in female NZB/NZW (F1) hybrid mice by cyclosporin A. Clin Exp Immunol, 59, 1–9
Gunn, HC (1986). Successful treatment of autoimmunity in (NZB x NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: I. reduction of autoantibodies. Clin Exp Immunol, 64, 225–233
Laupacis, N, Gardell, C, Dupre, J et al. (1983). Cyclosporin prevents diabetes in BB Wistar rats. Lancet, i, 10–12
Borel, JF, Fewer, C, Gubler, HU and Stahelin, H (1976). Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions, 6, 468–475
Kaibara, N, Hotokebuchi, T, Takagishi, K et al. (1984). Pathogenetic difference between collagen arthritis and adjuvant arthritis. J Expt Med, 159, 1388–1396
Yocum, DE, Allen, JB, Wahl, SM et al. (1986). Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats. Arthitis Rheum, 29, 262–273
Nussenblatt, RB, Rodrigues, MM, Salinas-Carmona, MC et al. (1982). Modulation of experimental autoimmune uveitis with cyclosporin A. Arch Ophthal, 100, 1146–1149
Bolton, C, Borel, JF, Cuzner, ML et al. (1982). Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis. J Neurol Sci, 56, 147–153
Schuller-Levis, GB, Kozlowski, PB and Wisniewski, HM (1986). Cyclosporin A treatment of an induced attack in a chronic relapsing model of experimental allergic encephalomyelitis. Clin Immunol Immunopathol, 40, 244–252
Takagishi, K, Kaibara, N, Hotokebuchi, T et al. (1986). Effects of cyclosporin on collagen induced arthritis in mice. Ann Rheum Dis, 45, 339–344
Kaibara, N, Hotokebuchi, T, Takagishi, K and Katsuki, I (1983). Paradoxical effects of cyclosporin A on collagen arthritis in rats. J Exp Med, 158, 2007–2015
Wiesinger, D and Borel, JF (1980). Studies on the mechanism of action of cyclosporin A. Immunobiology, 156, 454–463
Leapman, SB, Filo, RS, Smith, EJ and Smith, PG (1980). In vitro effects of cyclosporin A on lymphocyte subpopulations. I. Suppressor cell sparing by cyclosporin A. Transplantation, 30, 404–408
Kupiec-Weglinski, JW, Filho, MA, Strom, TB and Tilney, NL (1984). Sparing of suppressor cells: a critical action of cyclosporine. Transplantation, 38, 97–101
Kino, T, Hatanaka, H, Miyata, S et al. (1987). FK-506, a novel immunosuppressant isolated froma Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot, 40, 1256–1265
Inamura, N, Nakahara, K, Kino, T et al. (1988). Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK-506. Transplantation, 45, 206–209
Ochiai, T, Nakajima, K, Nagata, M et al. (1987). Studies of the induction and maintenance of long-term graft acceptance by treatment with FK-506 in heterotopic cardiac allotransplantation in rats. Transplantation, 44, 734–733
Ochiai, T, Nagata, M, Nakajima, K et al. (1987). Studies of the effects of FK-506 on renal allografting in the beagle dog. Transplantation, 44, 729–733
Inamura, N, Hashimoto, M, Nakahara, K et al. (1988). Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol, 46, 82–90
Sawada, S, Suzuki, G, Kawase, Y and Takaku, F (1987). Novel immunosuppressive agent, FK-506. In vitro effects on the cloned T cell activation. J Immunol, 139, 1797–1803
Cosimi, AB (1983). The clinical usefulness of antilymphocyte antibodies. Transplant Proc, 15, 583–589
Glass, NR, Miller, DT, Sollinger, HW and Beizer, FO (1983). A comparative study of steroids and heterologous antiserum in the treatment of renal allograft rejection. Transplant Proc, 15, 617–621
Russell, PS, Colvin, RB and Cosimi, AB (1984). Monoclonal antibodies for the diagnosis and treatment of transplant rejection. Annu Rev Med, 35, 63–79
Ortho Multicenter Transplant Study Group (1985). A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med, 313, 337–342
Gordon, RD, Starzl, TE, Fung, JJ et al. (1987). Monoclonal antibody therapy with ciclosporin and steroids in nonmatched cadaveric renal transplants. Nephron, 46,suppl. I, 56–59
Gordon, RD, Tzakis, AG, Iwatsuki, S et al. (1988). Experience with Orthoclone OKT3 monoclonal antibody in liver transplantation. Am J Kid Dis, 11, 141–144
Chatenoud, L, Jonker, M, Villemain, F et al. (1986). The human response to the OKT3 monoclonal antibody is oligoclonal. Science, 232, 1406–1408
Shield, CF, Norman, DJ, Marlett, P et al. (1987). Comparison of antimouse and anti-horse antibody production during the treatment of allograft rejection with OKT3 or antithymocyte globulin. Nephron, 46,Suppl. 1, 48–51
Cosimi, AB, Burton, RC and Kung, PC (1981). Evaluation in primate renal allograft recipients of monoclonal antibody to human T-cell subclasses. Transplant Proc, 13, 499
Wegelius, O, Laine, V, Lindstrom, B and Klockars, M (1970). Fistula of the thoracic duct as immunosuppressive treatment in rheumatoid arthritis. Acta Med Scand, 187, 539–544
Cosimi, AB, Colvin, RB, Burton, RC et al. (1981). Use of monoclonal antibodies to T-cell subsets for immunological monitoring and treatment in recipients of renal allografts. N Engl J Med, 305, 308–314
Bell, JD, Marshall, GD, Shaw, BA et al. (1983). Alterations in human thoracic duct lymphocytes during thoracic duct drainage. Transplant Proc, 15, 677–680
Obert, HJ and Hofschneider, PH (1985). Interferon bei chronischer Polyarthritis. Dtsch Med Wochenschr, 100, 1766–1769
Schindler, J, Kennedy, SM and Wolfe, F (1988). Potential of gamma interferon in rheumatoid arthritis. In: Advances in Inflammation Research, Vol. 12, ed A Lewis, N Ackerman and I Otterness (New York: Raven Press), pp. 305–311
Seitz, M, Manz, G and Franke, M (1986). Einsatz von rekombinatem Human-Interferon Gamma bei Patienten mit rheumatoider Arthritis. Z Rheumatol, 45, 93–99
Lemmel, EM, Franke, M, Gaus, W et al. (1987). Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int, 7, 127–132
Lemmel, E-M, Obert, HJ and Hofschneider, PH (1988). Low-dose gamma interferon in treatment of rheumatoid arthritis. Lancet, i, 598
Tosato, G, Steinberg, A and Blaese, RM (1981). Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med, 305, 1238–1243
Lotz, M, Tsoukas, CD, Fong, S et al. (1985). Regulation of Epstein-Barr virus infection by recombinant interferon. Selected sensitivity to IFN-gamma. Eur J Immunol, 15, 520–525
Panitch, HS, Haley, AS, Hirsch, RL and Johnson, KP (1986). A trial of gamma interferon in multiple sclerosis: clinical results. Neurology, 36,Suppl. 1, 285
Shidani, B, Colle, JH, Motta, I and Truffa-Bachi, P (1983). Effect of cyclosporin A on the induction and activation of B memory cells by thymus-independent antigens in mice. Eur J Immunol, 13, 359–363
Tosato, G, Pike, SE, Koski, IR and Blaese, RM (1982). Selective inhibition of immunoregulatory cell function by cyclosporin A. J Immunol, 128, 1986–1991
Wang, BS, Heacock, EH, Collins, KH et al. (1981). Suppressive effects of cyclosporin A on the induction of alloreactivity in vitro and in vivo. J Immunol, 127, 89–93
Weil, C (1984). Cyclosporin A: review of results in organ and bone-marrow transplantation in man. Med Res Rev, 4, 221–265
O’Connor, GR (1982). Epidemiology and pathogenesis of the ocular and cerebral forms of Behçet’s disease. Behçet’s Disease, ed. G Inaba (Tokyo: University of Tokyo Press), pp. 115–126
Nussenblatt, RB, Gery, I, Ballintine, EJ and Wacker, WB (1980). Cellular responsiveness of uveitis patients to retinal S-antigen. Am J Ophthalmol, 89, 173–179
Ohno, S (1981). Voght-Koyanagi, and Harada’s diseases. Trans Ophthalmol Soc UK, 101, 335–341
Sakane, T, Kotani, H, Takada, S and Tsunematsu, T (1982). Functional aberration of T cell subsets in patients with Behçet’s disease. Arthritis Rheum, 25, 1343–1351
Bottazzo, GF, Florin-Christensen, A and Doniach, D (1974). Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet, ii, 1279–1283
MacCuish, AC and Irvine, WJ (1975). Autoimmunological aspects of diabetes mellitus. Clin Endocrinol, 4, 435–471
Nerup, J, Andersen, OO, Bendixen, G et al. (1974). Cell-mediated immunity in diabetes mellitus. Proc R Soc Med, 67, 506–513
Assan, R, Debray-Sachs, M, Laborie, C et al. (1985). Metabolic and immunological effects of cyclosporin in recently diagnosed type I diabetes mellitus. Lancet, i, 67–71
Stiller, CR, Dupré, J, Gent, M et al. (1984). Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science, 223, 1362–1367
Allison, MC and Pounder, RE (1984). Cyclosporin for Crohn’s disease. Lancet, i, 902–903
Bianchi, PA, Mondelli, M, Quatro di Palo, F and Ranzi, T (1984). Cyclosporin for Chrohn’s disease. Lancet, i, 1242
Gupta, S, Keshavarzian, A and Hodgson, HJF (1984). Cyclosporin in ulcerative colitis. Lancet, ii, 1277–1278
Thivolet, J, Barthelemy, H, Rigot-Muller, G and Bendelac, A (1985). Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet, i, 334–335
Isenberg, DA, Snaith, ML, Morrow, WJW et al. (1981). Cyclosporin A for the treatment of systemic lupus erythematosus. Int I Immunopharmacol, 3, 163–169
Miescher, PA and Miescher, A (1985). Combined Ciclosporin steroid treatment of systemic lupus erythematosus. In Ciclosporin in Autoimmune Diseases, ed. R Schindler, (Berlin: Springer Verlag), pp. 337–345
Feutren, G, Querin, S, Chatenoud, L, Noel, LH et al. (1985). The effects of Ciclosporin in twelve patients with severe systemic lupus. In Ciclosporin in Autoimmune Diseases, ed. R Schindler, (Berlin: Springer Verlag), pp. 366–372
van Rijthoven, AWAM, Dijkmans, BAC, Goei The, HS et al. (1986). Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Ann Rheum Dis, 45, 726–731
Forre, O, Bjerkhoel, F, Salvesen, CF et al. (1987). An open, controlled, randomized comparison of cyclosporin and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum, 30, 88–92
Weinblatt, ME, Coblyn, JS, Fraser, PA et al. (1987). Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum, 30, 11–17
Dougados, M and Amor, B (1987). Cyclosporin A in rheumatoid arthritis: preliminary clinical results of an open trial. Arthritis Rheum, 30, 83–87
Bliven, ML, Cunningham, AC and Otterness, IG (1988). A pharmacological study of the relationship between lymphocyte function and surface antigen expression. Agents Actions, 25
Chapman, JR, Griffiths, D, Harding, NGL and Morris, PJ (1985). Reversibility of cyclosporin nephrotoxicity after three months’ treatment. Lancet, i, 128–129
von Graffenried, B and Harrison, WB (1985). Renal function in patients with autoimmune diseases treated with cyclosporine. Transplant Proc, 17,Suppl. 1, 215–231
Dijkmans, BAC, van Rijthoven, AWAM, Goei The, HS et al. (1987). Effects of cyclosporin on serum creatinine in patients with rheumatoid arthritis. Eur J Clin Pharmacol, 31, 541–545
Bird, HA, Yu, H and Cooper, EH (1984). Renal proximal dysfunction in rheumatic diseases. Br Med J, 288, 1044–1045
Berg, KJ, Forre, O, Bjerkhoel, F et al. (1986). Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. Kidney Int, 29, 1180–1187
Breedveld, FC, Valentijn, RM, Westedt, ML and Weening, J (1985). Rapidly progressive glomerulonephritis with glomerular crescent formation in rheumatoid arthritis. Clin Rheumatol, 4, 353–359
Kimberly, RP, Bowden, RE, Keiser, HR and Plotz, PH (1978). Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med, 64, 804–807
Wegmueller, E (1985). Nicht-steroidale Antirheumatika und Nephrotoxizitat. Dtsch Med Wochenschr, 110, 469–472
Hiestand, PC, Gunn, HC, Gale, JM et al. (1985). Comparison of the pharmacological profiles of cyclosporine, (Nva2)-cyclosporine and (Val2)dihydro-cyclosporine. Immunology, 55, 249–255
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Kluwer Academic Publishers
About this chapter
Cite this chapter
Otterness, I.G., Bliven, M.L. (1989). The T cell as a therapeutic target. In: Rainsford, K.D., Velo, G.P. (eds) New Developments in Antirheumatic Therapy. Inflammation and Drug Therapy Series, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-1253-3_11
Download citation
DOI: https://doi.org/10.1007/978-94-009-1253-3_11
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7056-0
Online ISBN: 978-94-009-1253-3
eBook Packages: Springer Book Archive